Feb 18 (Reuters) - Septerna Inc SEPN.O:
SEPTERNA ANNOUNCES DISCONTINUATION OF SEP-786 PHASE 1 CLINICAL TRIAL AND PLANS TO ADVANCE NEXT-GENERATION ORAL SMALL MOLECULE PTH1R AGONIST
SEPTERNA INC - DECISION FOLLOWS SEVERE EVENTS OF ELEVATED BILIRUBIN IN PHASE 1 TRIAL
SEPTERNA INC - NO LIVER INJURY OR SERIOUS ADVERSE EVENTS IN PHASE 1 TRIAL
SEPTERNA INC - EXPECTS CASH POSITION TO SUPPORT OPERATIONS INTO 2027
SEPTERNA INC: ADVANCING MULTIPLE NEXT-GENERATION PTH1R AGONISTS WITH DISTINCT AND UNRELATED CHEMICAL STRUCTURES RELATIVE TO SEP-786
Source text: ID:nGNXbKM318
Further company coverage: SEPN.O
((reuters.briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.